162220-83-9

Basic information

• Product Name: diethyl {[(6-ethoxypyridin-3-yl)amino]methylidene}propanedioate
• Synonyms: Diethyl {[(6-ethoxypyridin-3-yl)amino]methylene}malonate; Diethyl 2-([(6-ethoxy-3-pyridinyl)amino]methylene)malonate; propanedioic acid, 2-[[(6-ethoxy-3-pyridinyl)amino]methylene]-, diethyl ester
• CAS NO: 162220-83-9
• Molecular Formula: C₁₅H₂₀N₂O₅
• Molecular Weight: 308.3297
• Mol File: 162220-83-9.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 386.6°C at 760 mmHg
• Flash Point: 187.6°C
• Density: 1.192g/cm³
• Vapor Pressure: 3.5E-06mmHg at 25°C
• Refractive Index: 1.54
• CAS DataBase Reference: diethyl {[(6-ethoxypyridin-3-yl)amino]methylidene}propanedioate(CAS DataBase Reference)
• NIST Chemistry Reference: diethyl {[(6-ethoxypyridin-3-yl)amino]methylidene}propanedioate(162220-83-9)
• EPA Substance Registry System: diethyl {[(6-ethoxypyridin-3-yl)amino]methylidene}propanedioate(162220-83-9)

Safety Data

• Hazardous Substances Data: 162220-83-9(Hazardous Substances Data)

Upstream product

• 52025-34-0 5-amino-2-ethoxypyridine 
• 87-13-8 diethyl 2-ethoxymethylenemalonate 

Relevant articles and documents

Synthesis and Purification of 6-Ethoxy-4-oxo-1,4-dihydro-[1,5] naphthyridine-3-carboxylic Acid Benzylamide

The synthesis of 6-ethoxy-4-oxo-1,4-dihydro-[1,5]naphthyridine-3- carboxylic acid benzylamide (1) on multikilogram scale is described. The major challenge for the synthesis of this quinolone GABA partial agonist was in the isolation of product of acceptable purity for clinical studies due to the insolubility of this compound. Also described are efforts to circumvent a high-temperature cyclization required for the synthesis of the quinolone ring system.

Condensed 4-aminopyridines with antirheumatic activity

Compounds of formula I STR1 and pharmaceutically acceptable salts thereof in which one of A or B represents N and the other represents N or C--R3 ; R1 represents hydrogen, halo, alkyl, hydroxy, carboxyalkenyl, alkoxycarbonylalkenyl, hydroxyalkyl, carboxyalkyl, alkoxycarbonylalkyl, alkoxy, halogenated alkyl, carboxy, alkoxycarbonyl, alkanoylamino or carbamoylalkenyl; R2 represents hydrogen, alkyl, halo, alkoxy, hydroxy, alkanoyloxy, or phenoxy; R3 represents hydrogen or alkyl; R4 represents hydrogen, halo, alkoxycarbonyl, cyano, benzyloxycarbonyl, alkanoyl, benzoyl, alkyl, carboxy, alkylthio or carbamoyl; R5 represents hydrogen or alkyl; R9 represents hydrogen or alkyl; R10 represents phenyl, pyridyl or pyrimidinyl substituted by OR6 and optionally further substituted wherein R6 represents hydrogen, alkyl, alkoxycarbonyl or carbamoyl, alicyclic hydrocarbon, phenyl, cycloalkylalkyl, arylalkyl or pyridyl; or when R10 represents phenyl, OR6 represents a monosaccharide group or a disaccharide group; which are antirheumatic agents. Compositions containing these compounds and processes to prepare them are also disclosed.